602.889.9700
opportunity analysis

Co-Diagnostics, Inc. to Present at the Lytham Partners Virtual Investor Conference on November 30, 2017 at 2:00 p.m. ET

Management to Review Investor Presentation and Conduct Q&A; Replay Available on Demand

November 22, 2017 -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced that Dwight Egan, chief executive officer of Co-Diagnostics, will present at the Lytham Partners Virtual Investor Conference on Thursday, November 30, 2017 at 2:00 p.m. ET (11:00 a.m. PT). The conference is a virtual event available over the internet, and interested parties may participate by following any of the links below at the time of the conference.

Event:              Lytham Partners Virtual Investor Conference

Date:               November 30, 2017

Time:               2:00 pm ET / 11:00am PT

Webcast:         http://ir.codiagnostics.com/events-and-presentations or by accessing the link here.

Interested parties around the world may view the live investor presentation and ask the speakers questions in real time.

A replay of the presentation will be available on demand following the conclusion of the live event at http://ir.codiagnostics.com/events-and-presentations or by accessing the link here.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Company Contact: Co-Diagnostics, Inc., Andrew Benson, Investor Relations, 801-438-1036, investors@codiagnostics.com

Investor Contact: Lytham Partners, Joe Diaz, Robert Blum, Joe Dorame, 602-889-9700, codx@lythampartners.com